28th Jun 2021 15:15
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | Millennium International Management LP |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | US98422L1070 |
Date of dealing | 25th June 2021 |
2. INTERESTS AND SHORT POSITIONS
a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 1,810,007 (2.727%)
| 1,115,075 (1.680%) | ||||
(2) Derivatives (other than options) | - | - | ||||
(3) Options and agreements to purchase/sell | - | - | ||||
Total | 1,810,007 (2.727%)
| 1,115,075 (1.680%) | ||||
b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
Ap20
1. DEALINGS (Note 4)
a. Purchases and sales
Purchase/sale |
Number of relevant securities | Price per unit (Note 5) (USD) |
Sale | 5,395 | 4.81 |
Purchase | 5,395 | 4.81 |
Sale | 20 | 4.61 |
Sale | 100 | 4.54 |
Sale | 10 | 4.70 |
Sale | 40 | 4.76 |
Sale | 19 | 4.74 |
Sale | 11 | 4.84 |
Sale | 16 | 4.38 |
Sale | 200 | 4.49 |
Sale | 160 | 4.43 |
Sale | 100 | 4.51 |
Sale | 124 | 4.72 |
Sale | 100 | 4.67 |
Sale | 100 | 4.74 |
Sale | 1,541 | 4.57 |
Sale | 3 | 4.62 |
Sale | 2,120 | 4.49 |
Sale | 10,064 | 4.54 |
Sale | 832 | 4.71 |
Sale | 8,318 | 4.53 |
Sale | 34,865 | 4.52 |
Sale | 7,554 | 4.51 |
Sale | 451 | 4.56 |
Sale | 500 | 4.55 |
Sale | 357 | 4.50 |
Sale | 513 | 4.70 |
Sale | 779 | 4.75 |
Sale | 9,056 | 4.79 |
Sale | 502 | 4.73 |
Sale | 4,104 | 4.68 |
Sale | 12,250 | 4.72 |
Sale | 7,201 | 4.78 |
Sale | 600 | 4.67 |
Sale | 3,202 | 4.74 |
Sale | 409 | 4.84 |
Sale | 5,533 | 4.77 |
Sale | 2,213 | 4.80 |
Sale | 5,532 | 4.83 |
Sale | 1,328 | 4.44 |
Sale | 18 | 4.59 |
Sale | 1,000 | 4.57 |
Sale | 352 | 4.38 |
Sale | 200 | 4.81 |
Sale | 381 | 4.62 |
Sale | 200 | 4.39 |
Sale | 1,100 | 4.49 |
Sale | 300 | 4.54 |
Sale | 325 | 4.65 |
Sale | 100 | 4.66 |
Sale | 100 | 4.43 |
Sale | 100 | 4.71 |
Sale | 1,628 | 4.53 |
Sale | 1,000 | 4.52 |
Sale | 300 | 4.56 |
Sale | 700 | 4.50 |
Sale | 200 | 4.70 |
Sale | 300 | 4.82 |
Sale | 610 | 4.79 |
Sale | 200 | 4.73 |
Sale | 300 | 4.68 |
Sale | 297 | 4.72 |
Sale | 400 | 4.76 |
Sale | 300 | 4.78 |
Sale | 100 | 4.67 |
Sale | 200 | 4.74 |
Sale | 200 | 4.84 |
Sale | 200 | 4.77 |
Sale | 1,038 | 4.80 |
Sale | 100 | 4.91 |
Sale | 300 | 4.90 |
Sale | 100 | 4.46 |
Sale | 1,029 | 4.38 |
Sale | 500 | 4.36 |
Purchase | 3,729 | 4.63 |
Purchase | 760,274 | 4.81 |
Purchase | 600 | 4.71 |
Purchase | 11,469 | 4.56 |
Purchase | 600 | 4.75 |
Purchase | 832 | 4.79 |
Purchase | 200 | 4.73 |
Purchase | 600 | 4.72 |
Purchase | 900 | 4.78 |
Purchase | 300 | 4.89 |
Purchase | 382 | 4.67 |
Purchase | 200 | 4.74 |
Purchase | 100 | 4.84 |
Purchase | 1,833 | 4.80 |
Purchase | 400 | 4.86 |
Purchase | 600 | 4.83 |
Purchase | 700 | 4.87 |
Purchase | 198 | 4.91 |
Purchase | 2,055 | 4.85 |
Purchase | 120 | 4.93 |
Purchase | 133 | 4.92 |
Purchase | 767 | 4.88 |
Purchase | 1,470,308 | 4.81 |
Sale | 1,319 | 4.57 |
Sale | 194 | 4.63 |
Sale | 11,414 | 4.81 |
Sale | 5,008 | 4.62 |
Sale | 282 | 4.64 |
Sale | 501 | 4.48 |
Sale | 213 | 4.61 |
Sale | 850 | 4.54 |
Sale | 268 | 4.69 |
Sale | 355 | 4.60 |
Sale | 832 | 4.66 |
Sale | 147 | 4.71 |
Sale | 2,463 | 4.53 |
Sale | 911 | 4.47 |
Sale | 150 | 4.52 |
Sale | 6,927 | 4.56 |
Sale | 100 | 4.55 |
Sale | 400 | 4.50 |
Sale | 75 | 4.70 |
Sale | 33,532 | 4.75 |
Sale | 700 | 4.58 |
Sale | 900 | 4.79 |
Sale | 4,100 | 4.73 |
Sale | 100 | 4.68 |
Sale | 2,592 | 4.72 |
Sale | 1,552 | 4.76 |
Sale | 2,294 | 4.78 |
Sale | 333 | 4.89 |
Sale | 1,778 | 4.74 |
Sale | 30,766 | 4.77 |
Sale | 5,082 | 4.80 |
Sale | 400 | 4.86 |
Sale | 771 | 4.83 |
Sale | 200 | 4.91 |
Sale | 1,200 | 4.85 |
Purchase | 1 | 4.38 |
Purchase | 16,479 | 4.81 |
Purchase | 100 | 4.64 |
Purchase | 135 | 4.54 |
Purchase | 190 | 4.69 |
Purchase | 150 | 4.60 |
Purchase | 80 | 4.53 |
Purchase | 120 | 4.52 |
Purchase | 180 | 4.51 |
Purchase | 30 | 4.56 |
Purchase | 100 | 4.50 |
Purchase | 333 | 4.79 |
Purchase | 9 | 4.73 |
Purchase | 297 | 4.72 |
Purchase | 35 | 4.76 |
Purchase | 44 | 4.78 |
Purchase | 106 | 4.74 |
Purchase | 6 | 4.80 |
Purchase | 200 | 4.83 |
Purchase | 19 | 4.87 |
Purchase | 60 | 4.91 |
Purchase | 2,746 | 4.81 |
b. Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (GBP) (Note 5) |
|
|
|
|
i. Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
c. Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 28th June 2021 |
Contact name | Milos Naumovic |
Telephone number | +44 203 650 8203 |
If a connected EFM, name of offeree/offeror with which connected |
|
If a connected EFM, state nature of connection (Note 10) |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005395/en/
Copyright Business Wire 2021
Related Shares:
Xeris Biopharma